IL4 and colonic neoplasm: Blocking of IL4R with IL4Rα antagonist or anti-IL4 neutralizing antibodies sensitized CD133-expressing colon cancer stem cells to conventional the chemotherapeutics oxaliplatin and 5-FU [38].